TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24256460
Drug: Calcipotriol-betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriol-betamethasone dipropionate ointment (CBD)
Study: 23021506
Drug: PHiD-CV co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV co-administered with routine childhood vaccines
Study: 19782914
Drug: Selective inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective inhibitors of factor Xa and thrombin
Study: 19782914
Drug: Conventional anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticoagulants (heparins and vitamin K antagonists)
Study: 17313293
Drug: 6‐mg x
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mg x kg(‐1) dose of caffeine
Study: 17313293
Drug: 3‐mg x
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mg x kg(‐1) dose of caffeine
Study: 11677377
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + Hydrochlorothiazide (12.5 mg/day)
Study: 11677377
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + Benazepril (10 mg/day)
Study: 11677377
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg/day) alone
Study: 9674442
Drug: Anabolic steroids
Normalized name: ANABOLIC STEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroids (250 mg testosterone i.m. at baseline and 12 mg oral stanozolol daily for 27 weeks)
Study: 8023059
Drug: DFO (Deferoxamine)
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFO (Deferoxamine) at a low dose of 10 mg/kg body weight per week
Study: 24628437
Drug: Intra-pocket lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-pocket lidocaine and prilocaine gel (2.5% each)
Study: 20488929
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine (group SAM; n = 28)
Study: 16146573
Drug: Implant supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant supported dentures
Study: 10063488
Drug: Ethanol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.2 g/kg)
Study: 7726267
Drug: Clotrimazole 100
Normalized name: clotrimazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 100 mg vaginal treatment for 7 days
Study: 31035665
Drug: Low Amplitude
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Amplitude Seizure Therapy (LAP‐ST) at 500mA
Study: 31035665
Drug: Standard Right
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Right Unilateral Electroconvulsive Therapy (RUL ECT) at 900 mA
Study: 29111172
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling plus oral nutritional supplements (ONS)
Study: 29111172
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling without oral nutritional supplements (ONS)
Study: 25268205
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cohort 1)
Study: 25268205
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with a monoclonal antibody (cohort 2)
Study: 22473458
Drug: Additional ARB
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional ARB therapy
Study: 16223969
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus medical management for medication taper (CBT-MM)
Study: 8957641
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream with particles
Study: 8957641
Drug: Silicone-containing cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-containing cream
Study: 1349458
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 or 40 mg/day)
Study: 1349458
Drug: Betaxolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol (10 or 20 mg/day)
Study: 24051391
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% mixed with propofol formulations
Study: 12492710
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of daclizumab (2 mg/kg)
Study: 12492710
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of daclizumab (2nd dose, 1 mg/kg)
Study: 12492710
Drug: Daclizumab levels
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab levels of 1 micro g/mL or greater
Study: 1591091
Drug: Chemotherapy (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (six courses of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) followed by 4 courses of epirubicin)
Study: 1591091
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy and tamoxifen
Study: 1591091
Drug: Concurrent or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent or sequential use of chemotherapy and tamoxifen
Study: 30935324
Drug: Sham spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham spinal manipulative therapy (sham SMT)
Study: 19650422
Drug: Burch suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burch suspension
Study: 15209619
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg orally three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Study: 15209619
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Study: 2731558
Drug: Full contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full contrast dose (282 mg I/kg body weight)
Study: 2731558
Drug: Half contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half contrast dose (141 mg I/kg body weight)
Study: 31295390
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush with CrissCross and tapered bristle technology (Oral-B CrossAction Ultrathin); brushed twice daily for 4 weeks.
Study: 31295390
Drug: Traditional flat-trim
Normalized name: phentermine hydrochloride Oral Capsule [Oby-Trim]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional flat-trim design and regular non-tapered bristles (Oral-B Indicator Soft 35); brushed twice daily for 4 weeks.
Study: 19179885
Drug: Placebo (dilute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dilute preparation of Pregestamil formula)
Study: 14688021
Drug: Variant SULT1A1
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variant SULT1A1 genotype (638GA or AA) with cumulative smoking dose
Study: 9331014
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (4-16 mg once-daily)
Study: 21964277
Drug: Citalopram (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (flexible doses) for up to 14 weeks
Study: 19109962
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered intravenously within 4 weeks of surgery and continued for 1 year
Study: 10467830
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg/day for 3 months)
Study: 2319316
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with adjuvant chemotherapy (CCNU, vincristine, and prednisone)
Study: 2319316
Drug: Chemotherapy (CCNU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CCNU, vincristine, and prednisone) in patients with more extensive tumors
Study: 2319316
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (radiation therapy with and without chemotherapy)
Study: 536969
Drug: Bendrofluazide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 2.5 mg twice a day
Study: 536969
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and bendrofluazide
Study: 30651036
Drug: Udenafil 75
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 75 mg daily
Study: 31320603
Drug: Vacuum sealing
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum sealing drainage (VSD) treatment combined with skin flap transplantation and antibiotic bone cement
Study: 25803642
Drug: Multivalent NoV
Normalized name: Dallergy Reformulated Nov 2011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivalent NoV VLP vaccine (genotypes GI.1/GII.4)
Study: 28755607
Drug: Cabozantinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (100 mg daily)
Study: 19565549
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment plus rheumatologic care program
Study: 16782719
Drug: Adenosine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (50 or 70 microg/kg/min) for 3 hours starting within 15 minutes of reperfusion therapy
Study: 15307977
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH), specifically dalteparin
Study: 9124466
Drug: Ketoconazole (steroidogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (steroidogenic enzyme inhibitor)
Study: 8066317
Drug: Weekly replaced
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly replaced vinyl urinary drainage bags (group C)
Study: 3113764
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) continuous infusion
Study: 30604373
Drug: TELE‐IBD system
Approvals — FDA: no, EMA: no, PMDA: no
Description: TELE‐IBD system (self-testing weekly)
Study: 26538205
Drug: COX-2 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX-2 + PPI (celecoxib 200 mg twice daily + rabeprazole 20 mg once daily)
Study: 26538205
Drug: COX-2 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX-2 + placebo (celecoxib 200 mg twice daily + placebo)
Study: 24949820
Drug: As needed
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As needed treatment
Study: 22130905
Drug: Relapse prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse prevention therapy (RPT)
Study: 12482641
Drug: Control (diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (diet or metformin)
Study: 8383397
Drug: Lisinopril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (2.5 mg o.d. initially, increased to 5 mg and 10 mg o.d.)
Study: 8383397
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg t.i.d. initially, increased to 12.5 mg and 25 mg t.i.d.)
Study: 27340360
Drug: lafutidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lafutidine (10 mg, twice daily)
Study: 27340360
Drug: lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (30 mg, once daily)
Study: 23554851
Drug: Clonazepam 1
Normalized name: clonazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 1 mg
Study: 23554851
Drug: Tolterodine 1
Normalized name: tolterodine 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 1 mg (active placebo)
Study: 23554851
Drug: Intramuscular pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pain models
Study: 20825071
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (Lucentis) administered in doses of 0.3 or 0.5 mg into the vitreous body
Study: 1931705
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (IFN alpha-2b) with reduced doses
Study: 6277355
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg delta 9THC
Study: 6277355
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg delta 9THC
Study: 6277355
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg delta 9THC
Study: 31186121
Drug: 7-day ibuprofen
Normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day ibuprofen (600 mg three times a day)
Study: 31186121
Drug: 3-day ibuprofen
Normalized name: ibuprofen 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day ibuprofen (600 mg three times a day for 3 days, then placebo for 4 days)
Study: 23686032
Drug: Motor complications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor complications of PD therapy
Study: 23686032
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication profiles
Study: 19121446
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker alone
Study: 19121446
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker plus digoxin
Study: 19121446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no beta blocker or digoxin)
Study: 17224434
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) - no particular preparation
Study: 9135194
Drug: Clonidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (5 micrograms.kg‐1) administered orally 90 min before surgery
Study: 2405613
Drug: Nicardipine (60-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60-90 mg/day)
Study: 2405613
Drug: Nicardipine (30-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (30-90 mg/day)
Study: 2405613
Drug: Nicardipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (mean dose 69.4 mg/day)
Study: 2405613
Drug: Nicardipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60 mg/day)
Study: 31688431
Drug: Oral bicarbonate
Normalized name: sodium bicarbonate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bicarbonate on top of hydration
Study: 31688431
Drug: Intravenous bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bicarbonate on top of hydration
Study: 28472528
Drug: Internet Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Cognitive Behavioral Therapy for insomnia (CBTi)
Study: 28472528
Drug: In-Person Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-Person Cognitive Behavioral Therapy for insomnia (CBTi)
Study: 24521895
Drug: Trial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial group (n = 24) received solifenacin succinate (5 mg, once a day) and naftopidil (25 mg, every evening)
Study: 16949486
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice a day (n = 16)
Study: 10823767
Drug: Oral inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inactivated whole cell Vibrio cholerae plus recombinant B subunit cholera vaccine
Study: 6441194
Drug: Photons (subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photons (subgroup treatment for larynx cancer)
Study: 18361754
Drug: Pickles (PCK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pickles (PCK) (approximately 1,400 mg of acetic acid daily)
Study: 18361754
Drug: Vinegar (VIN)
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinegar (VIN) (2,800 mg of acetic acid daily)
Study: 18361754
Drug: Commercial vinegar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial vinegar pills (REF) (30 mg of acetic acid daily)
Study: 12766653
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with 30 mg of ketorolac
Study: 9664951
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) - 7 x 4 mg/kg body weight i.v.
Study: 9664951
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) - 3 x 250 mg i.v.
Study: 2785355
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of propofol, 18 mg.kg‐1.h‐1 for the first 30 min and 15 mg.kg‐1.h‐1 thereafter
Study: 28946866
Drug: Micronutrient powders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powders (MNPs) given daily to caregivers of infants in the treatment group.
Study: 23945720
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg Zn/d)
Study: 20598480
Drug: Percutaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous treatment with ePTFE/nitinol self-expanding stent graft (n = 50)
Study: 20598480
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with femoral to above-knee popliteal artery bypass using synthetic conduit (n = 50)
Study: 16697124
Drug: Propranolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (100 mg/day)
Study: 16697124
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amantadine (300 mg/day) and propranolol (100 mg/day)
Study: 12743863
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using the photosensitizer SQN 400 and interstitial photodynamic laser treatment
Study: 12743863
Drug: Photodynamic laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic laser therapy
Study: 28904371
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose insulin infusion
Study: 11302998
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose insulin infusion
Study: 7908410
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil)
Study: 7908410
Drug: Moderate-dose and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose and low-dose adjuvant chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil)
Study: 3265525
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fluoxetine
Study: 3265525
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptyline + 5 mg diazepam
Study: 3265525
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 5 mg diazepam
Study: 332196
Drug: Cycloalliin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloalliin, single oral dosage
Study: 25675384
Drug: RM-493 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM-493 (1 mg/24 h)
Study: 22397264
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement containing D‐phenylalanine, L‐glutamine and L‐5‐hydroxytriptophan
Study: 19715914
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with Cyclosporine and Steroids (SRL-CsA-ST)
Study: 19715914
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with Steroids after Cyclosporine withdrawal (SRL-ST)
Study: 18236765
Drug: Gout treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gout treatment with colchicine
Study: 9886905
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg daily
Study: 9886905
Drug: Co-amilozide (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amilozide (hydrochlorothiazide 25 mg/amiloride 5 mg) once daily
Study: 8057222
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn++ as sulfate daily
Study: 8057222
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Zn++ as sulfate daily
Study: 8057222
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Zn++ as sulfate daily (control)
Study: 29688617
Drug: Upadacitinib extended-release
Normalized name: upadacitinib Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib extended-release (ER) formulation 15 mg once daily
Study: 29688617
Drug: Upadacitinib extended-release
Normalized name: upadacitinib Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib extended-release (ER) formulation 30 mg once daily
Study: 29688617
Drug: Upadacitinib extended-release
Normalized name: upadacitinib Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib extended-release (ER) formulation
Study: 22900449
Drug: Atomized administration
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomized administration of intranasal ketamine (INK)